Real-world impact of fremanezumab on migraine-related health care utilization and costs in patients with common comorbidities, acute medication overuse, or difficult-to-treat migraine

被引：0
|
作者：
Buse, D. C. [1 ,2 ]
Driessen, M. T. [3 ]
Krasenbaum, L. J. [4 ]
Seminerio, M. J. [5 ,6 ]
Carr, K. [5 ]
Ortega, M. [5 ]
Packnett, E. R. [7 ]
机构：
[1] Albert Einstein Coll Med, Dept Neurol, New York, NY USA
[2] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA
[3] Teva Pharmaceut, Amsterdam, Netherlands
[4] Teva Branded Pharmaceut Prod R&D Inc, W Chester, PA USA
[5] Teva Pharmaceut, Parsippany, NJ USA
[6] Teva Pharmaceut, W Chester, PA USA
[7] IBM Watson Hlth, Cambridge, MA USA
来源：
HEADACHE | 2022年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-91
引用
收藏
页码：80 / 81
页数：2
相关论文
共 50 条
  • [41] Prophylaxis treatment with topiramate in migraine patients with evidence of overuse of acute medications: Effect on health care resource utilization and cost
    Pesa, J.
    Thayer, S.
    Rupnow, M.
    Biondi, D.
    HEADACHE, 2008, 48 : S22 - S23
  • [42] REAL-WORLD IMPACT OF ERENUMAB ON ADHERENCE, WORK ABSENTEEISM, AND RESCUE MEDICATION UTILIZATION AMONG PATIENTS WITH MIGRAINE: RESULTS OF AN OUTCOMES-BASED AGREEMENT
    Swart, E. C. S.
    Peasah, S. K.
    Huang, Y.
    Manolis, C.
    Good, C.
    VALUE IN HEALTH, 2024, 27 (06) : S366 - S366
  • [43] A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication
    Louise Lombard
    Mallory Farrar
    Wenyu Ye
    Yongin Kim
    Sarah Cotton
    Andrew S. Buchanan
    James Jackson
    Shivang Joshi
    The Journal of Headache and Pain, 2020, 21
  • [44] A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication
    Lombard, Louise
    Farrar, Mallory
    Ye, Wenyu
    Kim, Yongin
    Cotton, Sarah
    Buchanan, Andrew S.
    Jackson, James
    Joshi, Shivang
    JOURNAL OF HEADACHE AND PAIN, 2020, 21 (01):
  • [45] Real-world effectiveness and tolerability of fremanezumab for the preventive treatment of migraine in patients using concomitant gepants for acute treatment in a US neurology practice
    Eugeni, P.
    HEADACHE, 2022, 62 (07): : 927 - 927
  • [46] Long-term impact of fremanezumab on response rate, acute headache medication use, and disability in episodic migraine patients with acute medication overuse at baseline: results of a 1-year study
    Lipton, Richard M.
    Turner, Ira
    Cohen, Joshua M.
    Gandhi, Sanjay K.
    Yang, Ronghua
    Ning, Xiaoping
    Elms, Shawn
    CEPHALALGIA, 2019, 39 : 247 - 248
  • [47] Long-Term Impact of Fremanezumab on Response Rate, Acute Headache Medication Use, and Disability in Episodic Migraine Patients with Acute Medication Overuse at Baseline: Results of a 1-Year Study
    Lipton, R. B.
    Turner, I. M.
    Cohen, J. M.
    Gandhi, S. K.
    Yang, R.
    Ning, X.
    HEADACHE, 2019, 59 : 113 - 114
  • [48] Long-term impact of fremanezumab on response rate, acute headache medication use, and disability in chronic migraine patients with acute medication overuse at baseline: results of a 1-year study
    Silberstein, Stephen D.
    Kudrow, David
    Cohen, Joshua M.
    Gandhi, Sanjay K.
    Yang, Ronghua
    Ning, Xiaoping
    Blaiss, Cory
    CEPHALALGIA, 2019, 39 : 214 - 214
  • [49] Long-Term Impact of Fremanezumab on Response Rate, Acute Headache Medication Use, and Disability in Chronic Migraine Patients with Acute Medication Overuse at Baseline: Results of a 1-Year Study
    Silberstein, S. D.
    Kudrow, D.
    Cohen, J. M.
    Gandhi, S. K.
    Yang, R.
    Ning, X.
    HEADACHE, 2019, 59 : 113 - 113
  • [50] IMPACT OF ROFLUMILAST ON HEALTH CARE RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN REAL-WORLD SETTINGS
    Corman, S.
    Wan, Y.
    Sun, S. X.
    Gao, X.
    VALUE IN HEALTH, 2014, 17 (03) : A175 - A175
12345